x
Sign up for the Weekly Roundup below.
|
|||||||||||||||||||||||||
|
GBI’s information products track and illuminate virtually every aspect of China’s pharmaceutical industry. From pipeline and competitor data to performance benchmarks to physician data to pricing and tendering analytical tools, GBI provides the intelligence industry relies on to conduct its business. READ MORE...
Whether conducting a China opportunity assessment for a pharmaceutical, executing due diligence on an acquisition target, or advising on a licensing or M&A transaction, GBI leverages a unique, data-driven and systematic approach to its consulting services. READ MORE...
 Sign up for GBI's Weekly Roundup to track the news and get our views on China's pharma industry.
|
|||||||||||||||||||||||||
 Monday, February 6, 2012
Friday, February 3, 2012
This month, Binhui Ni, Head of Partnering & External Innovation (China) of the Global R&D unit of Sanofi aventis, sits down with GBI to share his insights and expertise in doing R&D partnering business in China, tapping on the value and challenges of identifying targets and looking into the commercial opportunities in those potential partners, assets and molecules, among others.
|
|||||||||||||||||||||||||
|
|||||||||||||||||||||||||
